OCU 300Alternative Names: OCU300
Latest Information Update: 22 Feb 2016
At a glance
- Originator University of Illinois at Chicago
- Developer Ocugen
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Graft-versus-host disease